


10/574422  
IAP20 Rec'd PCT/PTO 04 APR 2006

PATENT  
ATTORNEY DOCKET NUMBER: 50125/084002

Certificate of Mailing	
Date of Deposit: <u>April 4, 2006</u>	Label Number: <u>EV768764028US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as <b>"Express Mail Post Office to Addressee"</b> with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u>	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eggert Stockfleth	Art Unit:
Serial No.:	Not yet assigned	Examiner:
Filed:	April 4, 2006	Customer No.: 21559
Title:	THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRE-CANCEROUS LESION OF THE SKIN	

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed with the application.

10/574422


If there are any charges or any credits, please apply them to Deposit Account No.

AP20 Rec'd PCT/PTO 04 APR 2006

03-2095.

Respectfully submitted,

Date: 04 April 2006

  
\_\_\_\_\_  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

F:\50125\50125.048002 Information Disclosure Statement.doc

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/084002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/574422
		Applicant	Eggert Stockfleth
		Filing Date	April 4, 2006
		Group	
		IDS Filed	April 4, 2006
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,096,359	08/01/00	Bombardelli et al.			
	4,913,909	04/03/90	Hara et al.			
	4,673,530	06/16/87	Hara			
	4,613,672	09/23/86	Hara			
	4,248,789	02/03/81	Okada			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 2004/053097 A2	06/24/04	PCT			
	WO 2004/026323 A1	04/01/04	PCT			
	WO 2001/51048 A	07/19/01	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Cao, "Angiogenesis Inhibited By Drinking Tea," <i>Nature</i> , Macmillan Journals Ltd. 398:381 (1999).					
	Linden et al., "Chemoprevention of Non-Melanoma Skin Cancer: Experience With a Polyphenol From Green Tea," <i>European Journal of Cancer</i> 38:S24 (2002).					
	Linden et al., "Epigallocatechin Gallate in the Chemoprevention of Non-Melanoma Skin Cancer, With Biomarker Studies of Actinic Keratoses, Sun-Damaged, and Non Sun Damaged Skin: Results of Clinical Trial," <i>Frontiers of in Cancer Prevention Research</i> A113, p. 29 (2003).					
	McCarty, "Polyphenol-Mediated Inhibition of AP-1 Transactivating Activity May Slow Cancer Growth by Impeding Angiogenesis and Tumor Invasiveness," <i>Medical Hypothesis</i> 50:511-514 (1998)..					
	Mukhtar et al., "Green Tea Polyphenols Induce Apoptoseis and Alter the Progression fo Cell Cycle in Human Epidermoid Carcinoma Cells," <i>Proceedinsg of the American Association for Cancer Research and American Society of Clinical Oncology</i> 38:580 (1997).					
	Proniuk et al., "Preformulation Study of Epigallocatechin Gallate, a Promising Antioxidant for Topical Skin Cancer Prevention," <i>Journal of Pharmaceutical Sciences</i> 91:111-116 (2002).					
	Zhu et al., "Study of Tea Polyphenol as a Reversal Agent for Carcinoma Cell Lines Multidrug Resistance (Study of TP as a MDR Reversal Agent," <i>Nuclear Medicine and Biology</i> 28:735-740 (2001).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	